{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:07:34Z","timestamp":1773079654124,"version":"3.50.1"},"reference-count":10,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The activities of telavancin and vancomycin were compared in vitro and in the rabbit model of aortic valve endocarditis against a methicillin-resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            strain, COL, and a vancomycin-intermediate\n            <jats:italic>S. aureus<\/jats:italic>\n            (VISA) strain, HIP 5836. Telavancin was bactericidal in time-kill studies at a concentration of 5 \u03bcg\/ml against both COL and HIP5836. Vancomycin was bacteriostatic at 5 \u03bcg\/ml and bactericidal at 10 \u03bcg\/ml against COL and was bacteriostatic at 10 \u03bcg\/ml against VISA strain HIP 5836. Compared to untreated controls, a twice-daily regimen of 30 mg\/kg of telavancin reduced mean aortic valve vegetation titers of the COL strain by 4.7 log\n            <jats:sub>10<\/jats:sub>\n            CFU\/g after 4 days of therapy and sterilized 6\/11 vegetations compared to 3.4 log\n            <jats:sub>10<\/jats:sub>\n            CFU\/g with 3\/10 vegetations sterilized for a regimen of twice-daily vancomycin, 30 mg\/kg; these differences were not statistically significant. Telavancin was significantly more effective than vancomycin in the VISA model, producing a 5.5 log\n            <jats:sub>10<\/jats:sub>\n            CFU\/g reduction versus no reduction in CFU with vancomycin. In experiments comparing 2-day regimens of telavancin at 30 mg\/kg and 50 mg\/kg twice daily, organisms were rapidly eliminated from vegetations, but the effect was not different between the two doses. These results suggest that telavancin may be an effective treatment for endocarditis and other serious staphylococcal infections accompanied by bacteremia, including infections caused by staphylococci not susceptible to vancomycin.\n          <\/jats:p>","DOI":"10.1128\/aac.49.8.3163-3165.2005","type":"journal-article","created":{"date-parts":[[2005,7,27]],"date-time":"2005-07-27T10:52:45Z","timestamp":1122461565000},"page":"3163-3165","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":68,"title":["Efficacy of Telavancin in a Rabbit Model of Aortic Valve Endocarditis Due to Methicillin-Resistant\n            <i>Staphylococcus aureus<\/i>\n            or Vancomycin-Intermediate\n            <i>Staphylococcus aureus<\/i>"],"prefix":"10.1128","volume":"49","author":[{"given":"Andres G.","family":"Madrigal","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, San Francisco General Hospital, Department of Medicine, University of California at San Francisco, 1001 Potrero Avenue, San Francisco, California 94110"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Basuino","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, San Francisco General Hospital, Department of Medicine, University of California at San Francisco, 1001 Potrero Avenue, San Francisco, California 94110"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry F.","family":"Chambers","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, San Francisco General Hospital, Department of Medicine, University of California at San Francisco, 1001 Potrero Avenue, San Francisco, California 94110"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.884-888.2005"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.7.1747"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3043-3050.2004"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.08.067"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh156"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3602-3604.2003"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.195-201.2005"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.4.1020-1027.1998"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2004.04.006"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.8.3163-3165.2005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.49.8.3163-3165.2005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:58:27Z","timestamp":1645469907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.49.8.3163-3165.2005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1128\/AAC.49.8.3163-3165.2005"],"URL":"https:\/\/doi.org\/10.1128\/aac.49.8.3163-3165.2005","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]},"assertion":[{"value":"2004-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-04-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2005-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}